Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. Griffiths, R., R., Johnson, M., W., Richards, W., A., Richards, B., D., Jesse, R., MacLean, K., A., Barrett, F., S., Cosimano, M., P., & Klinedinst, M., A. Journal of Psychopharmacology, SAGE PublicationsSage UK: London, England, 10, 2017.
Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors [link]Website  abstract   bibtex   
Psilocybin can occasion mystical-type experiences with participant-attributed increases in well-being. However, little research has examined enduring changes in traits. This study administered psilocybin to participants who undertook a program of meditation/spiritual practices. Healthy participants were randomized to three groups (25 each): (1) very low-dose (1 mg/70 kg on sessions 1 and 2) with moderate-level (“standard”) support for spiritual-practice (LD-SS); (2) high-dose (20 and 30 mg/70 kg on sessions 1 and 2, respectively) with standard support (HD-SS); and (3) high-dose (20 and 30 mg/70kg on sessions 1 and 2, respectively) with high support for spiritual practice (HD-HS). Psilocybin was administered double-blind and instructions to participants/staff minimized expectancy confounds. Psilocybin was administered 1 and 2 months after spiritual-practice initiation. Outcomes at 6 months included rates of spiritual practice and persisting effects of psilocybin. Compared with low-dose, high-dose psilocybi...
@article{
 title = {Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors},
 type = {article},
 year = {2017},
 identifiers = {[object Object]},
 pages = {026988111773127},
 websites = {http://journals.sagepub.com/doi/10.1177/0269881117731279},
 month = {10},
 publisher = {SAGE PublicationsSage UK: London, England},
 day = {11},
 id = {470157ed-d9ed-37a0-9a4f-2a942d687038},
 created = {2017-11-10T18:19:04.613Z},
 accessed = {2017-10-26},
 file_attached = {false},
 profile_id = {38c6dbcb-2394-3f18-9217-58d777c08c69},
 group_id = {d9389c6c-8ab5-3b8b-86ed-33db09ca0198},
 last_modified = {2017-12-27T00:58:50.362Z},
 tags = {OA},
 read = {false},
 starred = {false},
 authored = {false},
 confirmed = {true},
 hidden = {false},
 citation_key = {Griffiths2017b},
 private_publication = {false},
 abstract = {Psilocybin can occasion mystical-type experiences with participant-attributed increases in well-being. However, little research has examined enduring changes in traits. This study administered psilocybin to participants who undertook a program of meditation/spiritual practices. Healthy participants were randomized to three groups (25 each): (1) very low-dose (1 mg/70 kg on sessions 1 and 2) with moderate-level (“standard”) support for spiritual-practice (LD-SS); (2) high-dose (20 and 30 mg/70 kg on sessions 1 and 2, respectively) with standard support (HD-SS); and (3) high-dose (20 and 30 mg/70kg on sessions 1 and 2, respectively) with high support for spiritual practice (HD-HS). Psilocybin was administered double-blind and instructions to participants/staff minimized expectancy confounds. Psilocybin was administered 1 and 2 months after spiritual-practice initiation. Outcomes at 6 months included rates of spiritual practice and persisting effects of psilocybin. Compared with low-dose, high-dose psilocybi...},
 bibtype = {article},
 author = {Griffiths, Roland R and Johnson, Matthew W and Richards, William A and Richards, Brian D and Jesse, Robert and MacLean, Katherine A and Barrett, Frederick S and Cosimano, Mary P and Klinedinst, Maggie A},
 journal = {Journal of Psychopharmacology}
}

Downloads: 0